Effect of long-term treatment with eyedrops for glaucoma on conjunctival bacterial flora

Infection and Drug Resistance

Volumn 4, Issue 1, 2011, Pages 191-196

  Honda, Rio ^a   Toshida, Hiroshi ^a   Suto, Chikako ^b   Fujimaki, Takuro ^b   Kimura, Tairo ^b   Ohta, Toshihiko ^a   Murakami, Akira ^b  

^a JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Benzalkonium chloride; Conjunctival flora; Eyedrop; Glaucoma; Levofloxacin

Indexed keywords

ANTIGLAUCOMA AGENT; EYE DROPS; LEVOFLOXACIN;

ADULT; AGED; ARTICLE; BACTERIAL FLORA; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CHRONIC DRUG ADMINISTRATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG INSTILLATION; FEMALE; GLAUCOMA; GRAM NEGATIVE BACTERIUM; HUMAN; INFECTION RATE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NONHUMAN;

EID: 84860447834     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S24250     Document Type: Article

References (16)

1. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18(5):205-215.
2. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004; 23(5):490-496.
3. Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86(7): 716-726.
4. Epstein SP, Ahdoot M, Yee K, Marcus E, Asbell PA. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther. 2009;25(2):113-119.
5. Martins EN, Alvarenga LS, Höfling-Lima AL, et al. Aerobic bacterial conjunctival flora in diabetic patients. Cornea. 2004;23(2):136-142.
6. Toshida H, Kogure N, Inoue N, Murakami A. Trends in microbial keratitis in Japan. Eye Contact Lens. 2007;33(2):70-73.
7. Inoue N, Toshida H, Mamada N, Kogure N, Murakami A. Contact lensinduced infectious keratitis in Japan. Eye Contact Lens. 2007;33(2): 65-69.
8. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. Approved standard, 7th ed. NCCLS Document M2-M7. Wayne, PA: NCCLS; 2000.
9. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility testing. Eleventh informational supplement. NCCLS Document M100-S11. Wayne, PA: NCCLS; 2001.
10. Sen EM, Yilmaz MB, Dansuk Z, et al. Effect of chronic topical glaucoma medications on aerobic conjunctival bacterial flora. Cornea. 2009;28(3): 266-270.
11. Orna G, Bottone EJ, Podos SM, Schumer RA, Asbell PA. Microbial contamination of medications used to treat glaucoma. Br J Ophthalmol. 1995;79(4):376-379.
12. Jokl DH, Wormser GP, Nichols NS, Montecalvo MA, Karmen CL. Bacterial contamination of ophthalmic solutions used in an extended care facility. Br J Ophthalmol. 2007;91(10):1308-1310.
13. Hori Y, Maeda N, Sakamoto M, Koh S, Inoue T, Tano Y. Bacteriologic profile of the conjunctiva in the patients with dry eye. Am J Ophthalmol. 2008;146(5):729-734.
14. Rhee DJ, Rapuano CJ, Belzer TL, Fraunfelder FW, editors. Physicians' desk reference for ophthalmic medicines. 33rd ed. Montvale, NJ: Thomson PDR; 2005.
15. Noecker RJ, Awadallah NS, Kahook MY. Travoprost 0.004%/timolol 0.5% fixed combination. Drugs Today (Barc). 2007;43(2):77-83.
16. Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144(4):533-540.